Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Closed
Phase 3
This trial is comparing volrustomig (MEDI5752) and chemotherapy with pembrolizumab and chemotherapy. It is for people with non small cell lung cancer that has spread to another part of the body.
You pronounce volrustomig as vole-rust-oh-mig.
Recruitment start: 11 December 2023
Recruitment end: 22 June 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tom Newsom-Davies
AstraZeneca
Last reviewed: 23 Jun 2026
CRUK internal database number: 19602